Amphastar Pharma (AMPH) Tops Q4 EPS by 33c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.33 better than the analyst estimate of $0.40. Revenue for the quarter came in at $135 million versus the consensus estimate of $127.25 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley Starts OGE Energy (OGE) at Equalweight
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook